therapy

Research therapeutics for Photodynamic Therapy (laser-activated photosensitizers). Photodynamic therapy (PDT), the treatment of disease with light and a light-activated therapeutic agent, has made strides towards a more general clinical acceptance over the past decade, but still has not reached the stage where it is recognized as a first line or primary treatment for solid subcutaneous cancerous tumors by most clinicians, including most surgeons and radiation oncologists. Until now.

the future

The space and facilities occupied by SensoPath Technologies for the past 10 years have been re-purposed by its owners, requiring us to close and vacate our synthetic laboratories and offices as of May 1, 2017. We retain some inventory available for shipment and we are working with a CRO to synthesize our patented dithiol products, followed by most of our catalog inventory. Please contact us for further information. PLEASE REFRESH YOUR BROWSER TO SEE CURRENT PRODUCT AVAILABILITY

forward thinking

Brenda Spangler has over 30 years experience in the field of protein chemistry and protein toxins, specializing in ligand-receptior molecular recognition - Read more in the 'About' section.

Charles Spangler has been working in the area of design and synthesis of highly conjugated organic materials for more than 30 years. His group has been involved with the design, synthesis, and characterization of new organic optical power limiting materials for eye and sensor protection, becoming one of the leaders in the design of new chromophores and dendrimers exhibiting reverse saturable absorption (RSA) and enhanced two-photon absorption (TPA) - Read more in the 'About' section.

What`s New?

Linkers Check out the Publications link in the About us tab for a list of publications using our linker products. Many new and creative uses are highlighted in recent publications.

Cancer ResearchSensoPath has completed a $1.5 M, 2 year NIH/National Cancer Institute SBIR contract award in collaboration with the University of Florida Dpartment of Biomedical Engineering, the College of Veterinary Medicine and the Wellman Center for Photomedicine, Massachusetts General Hospital/Harvard University for development of our Targeted Two-Photon Photodynamic Therapy therapeutic and imaging system.